Merck & Co. MRK Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 302.5%-1.3pp | 305%+3.2pp | 306.5%+7.9pp | 305.2%+9.5pp | 303.8%+10.4pp | |
| Net margin | 97.1%— | 110.8%— | 109.4%— | —— | —— | |
| Returns | ||||||
| Return on equity | 130.8%— | 151.2%— | 155.1%— | —— | —— | |
| Return on invested capital | 80.6%— | 93.4%— | 95.3%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 2.1×-0.2× | 2.2×-0.1× | 2.2×0.0× | 2.3×0.0× | 2.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.9×+0.3× | 6×+0.6× | 5.9×+0.5× | 5.6×+0.2× | 5.6×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 3.7×+0.2× | 3.3×-0.3× | 3.2×-0.6× | 3.3×-0.4× | 3.5×-0.3× | |
| Net debt / EBITDA | 6.9×— | 5.2×— | 4.9×— | —— | —— | |
| Valuation | ||||||
| Market capitalization | $969.99B-10.2% | $899.32B-24.3% | $889.71B-26.6% | $967.83B-18.3% | $1.08T-7.3% | |
| Price / earnings | 70.9×— | 50.6×— | 51×— | —— | —— | |
| Price / sales | 15×-2.1× | 14×-4.9× | 13.9×-5.7× | 15.2×-4.3× | 17×-2.4× | |
| Price / book | 19.6×-4.2× | 17.8×-9.6× | 18.3×-11.0× | 20.7×-8.4× | 23.8×-5.7× | |
| EV / EBITDA | 56.2×— | 44.5×— | 44.7×— | —— | —— | |
| Dividend yield | 13.7%+2.0pp | 14.5%+4.0pp | 14.5%+4.4pp | 13.3%+3.1pp | 11.7%+1.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Merck & Co.'s ratios come from?
- Every ratio is computed from Merck & Co.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
